PureTech Health PLC is a clinical stage biotherapeutics company. The Company is engaged in discovering, developing and commercializing medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases, and neurological and neuropsychological disorders, among others. The Companyâ€™s pipeline is comprised of 27 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization. The Companyâ€™s wholly owned pipeline consists of six therapeutic candidates including LYT-100, LYT-200, LYT-210, LYT-300, LYT-500, LYT-510, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. The Internal segment is advancing wholly owned programs which is focused on immunological, fibrotic and lymphatic system disorders.